Primmune Therapeutics

San Diego, CA · Founded 2017 · Privately Held (backing)

Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. Primmune Therapeutics is based in San Diego, CA and was founded in 2017. It was valued at $44 million at its early-stage round in Jan 2021, the last priced event on record. It has raised $63.2 million across 5 recorded rounds; the latest was a $13 million early-stage round in Oct 2020.

PMV mark · valuation
$44.0M
Oct 2026
Priced at
its early-stage round
Jan 2021
Total raised
$63.2M
Last round
Early Stage VC
Oct 2020

Who backs Primmune Therapeutics?

9 investors
InvestorType
Johnson & Johnson Innovation - JLABSOther
Polaris PartnersVenture capital
Samsara BioCapitalVenture capital
CAM CapitalFamily office
BioRock Ventures—
Biobrit—
Bioqube Ventures—
Charlie McDermott—
Oberland Capital—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Primmune Therapeutics investors

9 investors are on record for Primmune Therapeutics, including Johnson & Johnson Innovation - JLABS, Polaris Partners, Samsara BioCapital and CAM Capital. The early-stage round in Oct 2020 drew 12 investors.

Free account
More of Primmune Therapeutics with a free account
  • ·Watch Primmune Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 9 firms already write checks for companies like Primmune Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View